Centogene N.V. (CNTG)

NASDAQ: CNTG · IEX Real-Time Price · USD
1.27
-0.02 (-1.55%)
Jan 31, 2023, 4:00 PM EST - Market closed
-1.55%
Market Cap 34.39M
Revenue (ttm) 99.60M
Net Income (ttm) -52.57M
Shares Out 27.08M
EPS (ttm) -2.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,404
Open 1.34
Previous Close 1.29
Day's Range 1.26 - 1.35
52-Week Range 0.68 - 5.18
Beta -1.08
Analysts Buy
Price Target 2.55 (+100.79%)
Earnings Date Mar 28, 2023

About CNTG

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide ... [Read more]

Sector Healthcare
IPO Date Nov 7, 2019
Employees 808
Stock Exchange NASDAQ
Ticker Symbol CNTG
Full Company Profile

Financial Performance

In 2021, Centogene's revenue was 189.92 million, an increase of 47.94% compared to the previous year's 128.38 million. Losses were -46.41 million, 116.0% more than in 2020.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CNTG stock is "Buy." The 12-month stock price forecast is $2.55, which is an increase of 100.79% from the latest price.

Price Target
$2.55
(100.79% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. & ROSTOCK, Germany & BERLIN--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering...

Other symbols: TWST
3 weeks ago - Business Wire

CENTOGENE and Denali Therapeutics Extend World's Largest Observational Study on Parkinson's Disease Genetics

Working together to deliver data-driven, informative genotyping answers to accelerate and de-risk drug discovery, development, and commercialization for Parkinson's disease (PD) Working together to de...

3 weeks ago - GlobeNewsWire

Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development

Leveraging Rare Disease Insights Powered by the CENTOGENE Biodatabank and Centralized Multiomic Laboratories in Clinical Trials MORRISVILLE, N.C., and CAMBRIDGE, Mass.

3 weeks ago - PRNewsWire

CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

1 month ago - GlobeNewsWire

CENTOGENE Reports Second Quarter and First Half 2022 Financial Results

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

1 month ago - GlobeNewsWire

CENTOGENE Receives Nasdaq Non-Compliance Notice

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

1 month ago - GlobeNewsWire

CENTOGENE to Participate in Upcoming Conferences in December

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

2 months ago - GlobeNewsWire

CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan

Adding significant financial expertise with an impressive track record in value creation Adding significant financial expertise with an impressive track record in value creation

2 months ago - GlobeNewsWire

CENTOGENE to Participate in Upcoming Conferences in November

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

2 months ago - GlobeNewsWire

CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

3 months ago - GlobeNewsWire

CENTOGENE to Participate in Upcoming Partnering Conferences in October

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegene...

4 months ago - GlobeNewsWire

CENTOGENE Reaches 12,500 Patient Milestone in World's Largest Observational Study on Parkinson's Disease Genetics

Working together with Denali Therapeutics to accelerate data-driven precision medicine for the PD community

4 months ago - GlobeNewsWire

CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegene...

5 months ago - GlobeNewsWire

CENTOGENE Reports First Quarter 2022 Financial Results

On Track for FY 2022 Guidance

7 months ago - GlobeNewsWire

CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegene...

7 months ago - GlobeNewsWire

CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer

Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO

7 months ago - GlobeNewsWire

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

Working together on the world's first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18 Working together on the world's first treatment ...

8 months ago - GlobeNewsWire

CENTOGENE's CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework

CE-marked clinical decision support platform enables laboratories to provide best-in-class diagnostics of genetic diseases CE-marked clinical decision support platform enables laboratories to provide ...

9 months ago - GlobeNewsWire

CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics

Newly established WGS recommendations published in the European Journal of Human Genetics

9 months ago - GlobeNewsWire

CENTOGENE to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenera...

9 months ago - GlobeNewsWire

CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases

9 months ago - GlobeNewsWire

CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results

- Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance

11 months ago - GlobeNewsWire

CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 24, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, u...

11 months ago - GlobeNewsWire

CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, u...

11 months ago - GlobeNewsWire

CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer

ROSTOCK, Germany and BERLIN, March 17, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat ...

11 months ago - GlobeNewsWire